Randomized controlled trials establish strict inclusion and exclusion criteria in an effort to optimize the cohort of trial participants.
Dan Riskin
Advertisement
Articles by Dan Riskin
Applied Clinical Trials
The FDA has been working to enable greater adoption of RWE in clinical and regulatory decisions, as mandated by the 21st Century Cures Act.
Advertisement
Latest Updated Articles
- How to Transition RWE Studies from Non-Clinical to Regulatory-Grade
January 10th 2019
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Portfolio-Level Recruitment Strategy, Real-Time Burden Sampling, and Platinum-Free Bladder Cancer Therapy
2
Selective Safety Data Collection and the Case for Simpler Trials: Q&A with Rob DiCicco, TransCelerate Biopharma
3
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
4
ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development
5